Brian Orelli

Cutting-edge technology meets traditional healthcare.

By catering to the needs of medical professionals, Doximity could deliver in a big way.

Positive clinical results should be a good thing, right?

Pfizer’s foreseeable future looks strong.

Trial design may matter more than you think.

What happens after a trial’s results are negative -- or positive?

Author Dr. Frank David breaks down what investors should look for when it comes to trial design.

Do some drug trial participants see improvements just because they’re told they might?

Is it time to buy a basket of biotech stocks?

Novavax’s milestone means investors can now exhale.